-transparent.png){kind=logo}
To date there is no satisfactory serum or cerebrospinal fluid (CSF) metabolic marker with which to identify patients with ALS. The goal of finding a suitable marker will be more feasible following the identification of defined subgroups of patients with ALS. Some aspects of neurotransmitter chemistry in CSF seem worthy of further investigation, in particular, clarification of whether there is a significant elevation of CSF glutamate in a subgroup of patients and whether there are robust alterations in the noradrenaline transmitter system. It seems unlikely, in the face of present evidence, that the presence of aberrant exitatory amino acid transporter 2 transcripts in CSF will prove to be a useful marker of ALS. Increased levels of 3-nitrotyrosine and neurofilament light in CSF, while not entirely disease-specific for ALS, may nevertheless prove useful confirmatory markers of the disease and its progression.
P J Shaw, and
R Williams
January 2002,
Neurobiology of aging,
P J Shaw, and
R Williams
March 2006,
Neurology,
P J Shaw, and
R Williams
December 1980,
Annals of neurology,
P J Shaw, and
R Williams
January 1978,
Transactions of the American Neurological Association,
P J Shaw, and
R Williams
September 2005,
Pediatric neurology,
P J Shaw, and
R Williams
April 1986,
Annals of neurology,
P J Shaw, and
R Williams
January 1978,
Annals of clinical and laboratory science,
P J Shaw, and
R Williams
June 1985,
Infection and immunity,
P J Shaw, and
R Williams
December 2017,
Scientific reports,
P J Shaw, and
R Williams
October 1999,
Acta neurologica Scandinavica,
